Xiaobai Li

Beijing Normal University, Beijing, Beijing Shi, China 
face recognition
"Xiaobai Li"
Mean distance: 16.21 (cluster 23)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Zhou M, Shi X, Li X, et al. (2021) Constructing Silk Fibroin-Based Three-Dimensional Microfluidic Devices a Tape Mask-Assisted Multiple-Step Etching Technique. Acs Applied Bio Materials. 4: 8039-8048
Schupmann W, Li X, Wendler D. (2021) Acceptable Risks in Pediatric Research: Views of the US Public. Pediatrics
Wang J, Kong LA, Zhang L, et al. (2021) Breeding a Soybean Cultivar Heinong 531 with Peking-Type Cyst Nematode Resistance, Enhanced Yield and High Seed-Oil Contents. Phytopathology
Piacentino D, Grant-Beurmann S, Vizioli C, et al. (2021) Gut microbiome and metabolome in a non-human primate model of chronic excessive alcohol drinking. Translational Psychiatry. 11: 609
Li X, Wang Y, Jin L, et al. (2021) Development of fruit color in Rubus chingii Hu (Chinese raspberry): A story about novel offshoots of anthocyanin and carotenoid biosynthesis. Plant Science : An International Journal of Experimental Plant Biology. 311: 110996
Ovejero D, Hartley IR, de Castro Diaz LF, et al. (2021) PTH and FGF23 Exert Interdependent Effects on Renal Phosphate Handling: Evidence from Patients with Hypoparathyroidism and Hyperphosphatemic Familial Tumoral Calcinosis Treated with Synthetic Human PTH 1-34. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research
Li X, Jiang J, Chen Z, et al. (2021) Transcriptomic, Proteomic and Metabolomic Analysis of Flavonoid Biosynthesis During Fruit Maturation in . Frontiers in Plant Science. 12: 706667
Chen Z, Jiang J, Shu L, et al. (2021) Combined transcriptomic and metabolic analyses reveal potential mechanism for fruit development and quality control of Chinese raspberry (Rubus chingii Hu). Plant Cell Reports
Schupmann W, Li X, Wendler D. (2021) Do the Potential Medical Benefits of Phase 1 Pediatric Oncology Trials Justify the Risks? Views of the US Public. The Journal of Pediatrics
Hasni SA, Gupta S, Davis M, et al. (2021) Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nature Communications. 12: 3391
See more...